Business
GeneICE CRT update
GeneICE CRT update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release: 0700hrs Monday 10 September 2007\n\n VALIRX PLC \n\n (\"ValiRx\" or the \"Company\") \n\n GeneICE - CRT Research Update \n\nValiRx (AIM: VAL), the cancer therapeutics company, is pleased to provide an\nupdate on the research programme being conducted with Cancer Research\nTechnology Limited (\"CRT\"), on behalf of Cancer Research UK, on one of the\nproprietary GeneICE compounds developed by the Company's subsidiary, Cronos\nTherapeutics Ltd (\"Cronos\").\n\nAccording to the initial results released to the Company by CRT, the GeneICE\ncompound appears to arrest the development and terminate the existence of\ncancer cells, confirming earlier pre-clinical studies conducted by scientists\nin other research centres. The CRT studies suggested that GeneICE drug\ncandidates targeted to Bcl-2* restored apoptosis in six cancer cell lines by\npenetrating the walls of cancer cells and targeting the nucleus, leading to\ncell death.\n\nDr Satu Vainikka, CEO of ValiRx, added:\n\n\"The GeneICE technology is protected from a patent position and with continued\nresearch, the relevance of the GeneICE technology to a range of cancer\ntherapeutic applications will only increase.\"\n\nDr Jake Micallef, COO of ValiRx, commented:\n\n\"We are delighted by the latest findings which enable us and CRT to take the\nresearch activity on the GeneICE compound to its next stage of development.\"\n\n--- ENDS---\n\nNote to Editor:\n\n* Bcl-2 is recognised as a validated key target for the development of future\ncancer therapies.\n\nInformation on Cancer Research Technology Limited\n\nCRT is a specialist technology transfer company which aims to develop new\ndiscoveries in cancer research for the benefit of cancer patients. CRT is\nwholly owned by Cancer Research UK, the largest independent funder of cancer\nresearch in the world. CRT works closely with leading international cancer\nscientists and their institutes to protect intellectual property arising from\ntheir research and to establish links with commercial partners. CRT facilitates\nthe discovery, development and marketing of new cancer therapeutics, vaccines,\ndiagnostics and enabling technologies. Further information about CRT can be\nfound at www.cancertechnology.com\n\nInformation on ValiRx plc\n\nValiRx is a biopharmaceutical development company that is building a portfolio\...